3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
19
Phase 2
3
Phase 2/3
2
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Cisplatin
29
Carboplatin
28
Gemcitabine
27
Paclitaxel
26
pembrolizumab
24
Capecitabine
16
Pemetrexed
15
Bevacizumab
15
Docetaxel
14
Oxaliplatin
13
Fluorouracil
12
Drug Therapy
12
Nivolumab
10
130-nm albumin-bound paclitaxel
9
anlotinib
7
Trastuzumab
7
Injections
7
Rituximab
6
venetoclax
5
atezolizumab
5
Temozolomide
5
Leucovorin
5
Ipilimumab
5
Lenalidomide
4
Irinotecan
4
Interferon alpha-2
4
Folfox protocol
4
Dexamethasone
4
Azacitidine
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
INDUSTRY
×
budigalimab
×
Clear all
NCT06236438
2026-02-23
LIVIGNO-4
AbbVie
Phase 2/3
Recruiting
840 enrolled
NCT06109272
2025-08-15
LIVIGNO-2
AbbVie
Phase 2/3
Recruiting
660 enrolled